« Canadian Corporate News - Health Canada: Patients of Asian Ancestry Using Epilepsy Drug Carbamazepine May be at Increased Risk of Serious Skin Reactions.
Increasing Knowledge about Prevalent Bipolar Medicinal Options »

Business Wire - Biovail Announces Filing of Three ANDA’s; Generic Versions of Adalat CC 90mg, Procardia XL 90mg and Tegretol 400mg

Business Editors, Health/Medical Writers
TORONTO–(BW HealthWire)–Jan. 3, 2001
Biovail Corporation (NYSE:BVF)(TSE:BVF.) announced today it has filed with the Food and Drug Administration (FDA) Abbreviated New Drug Applications (ANDA) for its generic controlled-release versions of Adalat CC 90mg, Procardia XL 90mg and Tegretol 400mg. Adalat CC is sold by the Bayer Corporation in the United States and is indicated for the treatment of hypertension. Procardia XL is sold by Pfizer Inc. in the United States and is indicated for the treatment of hypertension and angina. Tegretol is sold by Novartis Pharmaceutical Corporation in the United States and is indicated for the treatment of epilepsy. Combined, these filings represent in excess of $220 million of brand sales based on the twelve-month period ended September 2000.

Most Popular
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
3 Questions No Job Seeker Ever Wants To Be Asked?
Business Plan Sample
13 Job Interview Mistakes To Avoid

Biovail, through its marketing partner Teva Pharmaceuticals, is currently marketing generic versions of Adalat CC (30mg and 60mg) and Procardia XL (60mg) dosage strengths. The total Adalat CC and Procardia XL brand sales value, including all strengths, is in excess of $800 million.
Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug delivery technologies.
“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission.
COPYRIGHT 2001 Business Wire
COPYRIGHT 2001 Gale Group